Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.67 |
| ▸ | INSR | P06213 | 6/20 | 0.67 |
| ▸ | JAK2 | O60674 | 3/20 | 0.66 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.66 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.65 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.57 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24255323 | 0.93 | ALK (0.57) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24255302 | 0.92 | ALK (0.77) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24258128 | 0.92 | ALK (0.57) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24255319 | 0.92 | ALK (0.64) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24255310 | 0.89 | ALK (0.74) | ALKLRRK2 | |
| SCHEMBL24258122 | 0.88 | LRRK2 (0.53) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24255320 | 0.88 | LRRK2 (0.63) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL26270495 | 0.85 | ALK (0.66) | ALKINSRJAK2SRCTNK2 | |
| SCHEMBL24255247 | 0.85 | TNK2 (0.65) | ALKJAK2SRCTNK2LRRK2 | |
| SCHEMBL24258116 | 0.84 | ALK (0.66) | ALKINSRJAK2SRCTNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022036312-A2 | INHIBITORS OF ACK1/TNK1 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |